NEURONET, the new Innovative Medicines Initiative (IMI) Coordination and Support Action (CSA) aiming to support and better integrate projects in the IMI Neurodegenerative Diseases (ND) portfolio, held its first Scientific Coordination Board (SCB) meeting on Tuesday 2nd July in Madrid, Spain. The meeting brought together the leaders of nine Innovative Medicine Initiative’s (IMI) Neurodegeneration projects: ADAPTED, AMYPAD, EMIF, EPAD, EQIPD, IMPRIND, MOPEAD, PHAGO and PRISM.
The project coordinator, Carlos Díaz from SYNAPSE Research Management Partners, explained the concept and approach of the NEURONET CSA, and then each SCB member had the opportunity to give a short presentation to introduce their project. These project presentations served as the basis for the afternoon discussion, which evolved around the potential synergies, priority areas and opportunities for collaboration between the projects.
At present, the SCB is formed by the scientific leaders of twelve IMI neurodegeneration projects in total (the nine aforementioned, plus AETIONOMY, ROADMAP, RADAR-AD and RADAR-CNS). The next SCB meeting will take place in October in The Hague, Netherlands.
NEURONET has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 821513. The JU receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA and Parkinson’s UK.
The main aim of NEURONET is to set up an efficient platform to boost synergy and collaboration across the IMI projects of the Neurodegenerative Disorders (ND) portfolio, assisting in identifying gaps, multiplying its impact, enhancing its visibility, and facilitating dovetailing with related initiatives in Europe and worldwide.